CN109957003A - 一种稳定的saa突变体及其在疾病检测中的应用 - Google Patents
一种稳定的saa突变体及其在疾病检测中的应用 Download PDFInfo
- Publication number
- CN109957003A CN109957003A CN201910297187.9A CN201910297187A CN109957003A CN 109957003 A CN109957003 A CN 109957003A CN 201910297187 A CN201910297187 A CN 201910297187A CN 109957003 A CN109957003 A CN 109957003A
- Authority
- CN
- China
- Prior art keywords
- protein
- mutant
- serum amyloid
- stability
- saa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title abstract description 12
- 201000010099 disease Diseases 0.000 title abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 12
- 230000035772 mutation Effects 0.000 claims abstract description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000001413 amino acids Chemical group 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims abstract description 9
- 239000004471 Glycine Substances 0.000 claims abstract description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000018417 cysteine Nutrition 0.000 claims abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004474 valine Substances 0.000 claims abstract description 4
- 239000004472 Lysine Substances 0.000 claims abstract description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 24
- 101710190759 Serum amyloid A protein Proteins 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000000869 mutational effect Effects 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- GHXRKGHKMRZBJH-UHFFFAOYSA-N boric acid Chemical compound OB(O)O.OB(O)O GHXRKGHKMRZBJH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 abstract description 27
- 101000869480 Homo sapiens Serum amyloid A-1 protein Proteins 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 13
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 238000003259 recombinant expression Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- MCKSLROAGSDNFC-ACZMJKKPSA-N Ala-Asp-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MCKSLROAGSDNFC-ACZMJKKPSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 1
- JPAWCMXVNZPJLO-IHRRRGAJSA-N Arg-Ser-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JPAWCMXVNZPJLO-IHRRRGAJSA-N 0.000 description 1
- JGIAYNNXZKKKOW-KKUMJFAQSA-N Asn-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N JGIAYNNXZKKKOW-KKUMJFAQSA-N 0.000 description 1
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 1
- YTXCCDCOHIYQFC-GUBZILKMSA-N Asp-Met-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTXCCDCOHIYQFC-GUBZILKMSA-N 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710150423 DNA nickase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- ZTNHPMZHAILHRB-JSGCOSHPSA-N Glu-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)NCC(O)=O)=CNC2=C1 ZTNHPMZHAILHRB-JSGCOSHPSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- SVZFKLBRCYCIIY-CYDGBPFRSA-N Ile-Pro-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVZFKLBRCYCIIY-CYDGBPFRSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- KGCLIYGPQXUNLO-IUCAKERBSA-N Leu-Gly-Glu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O KGCLIYGPQXUNLO-IUCAKERBSA-N 0.000 description 1
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- UZBQXELAFPCGRV-SZMVWBNQSA-N Met-Trp-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZBQXELAFPCGRV-SZMVWBNQSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- PMKIMKUGCSVFSV-CQDKDKBSSA-N Phe-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)N PMKIMKUGCSVFSV-CQDKDKBSSA-N 0.000 description 1
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 1
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 1
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 1
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101150025101 SAA1 gene Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 1
- IRAUYEAFPFPVND-UVBJJODRSA-N Val-Trp-Ala Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 IRAUYEAFPFPVND-UVBJJODRSA-N 0.000 description 1
- YAWNFGAHEUCLNJ-UHFFFAOYSA-N [B].OB(O)O Chemical group [B].OB(O)O YAWNFGAHEUCLNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种稳定的SAA突变体及其在疾病检测中的应用，包括将SAA蛋白进行定向突变，使第10位的半胱氨酸突变为赖氨酸，第26位的甘氨酸突变为脯氨酸，第50位的丝氨酸突变为缬氨酸，第66位的甘氨酸突变为脯氨酸，得到突变型蛋白的氨基酸序列如序列1所示。该突变型SAA1具有很高的稳定性，可应用于体外诊断试剂，提高了在临床疾病检测过程中的准确性。
Description
技术领域
本发明属于生物技术领域，具体而言，涉及一种与血清淀粉样蛋白(SAA)的稳定性显著关联的突变位点，以及突变型SAA蛋白及其在疾病检测中的应用。
背景技术
血清淀粉样蛋白A(serum amyloid A,SAA)是由活化的单核/巨噬细胞释放的细胞因子合成的载脂蛋白家族，为组织淀粉样蛋白A的前体物质，属急性时相反应蛋白(陈长强，顾志冬，樊绮诗.血清淀粉样蛋白A在疾病应用中的研究进展[J].检验医学,2012,27(9):776-779.)。它与C反应蛋白(CRP)一样是急性期的敏感标志物，炎症、感染性和非感染性疾病期间，在血液中的浓度能在数小时内急剧升高。已有研究表明，在细菌、真菌及病毒感染、动脉粥样硬化、心血管疾病、急性移植排斥反应、肿瘤等疾病中均可检测到血清SAA升高。尤其是当病毒感染、心血管疾病、移植排斥反应时，SAA的敏感性可高于CRP，对临床诊断有更好的参考价值。
目前，SAA的检测方法主要有以下几种：(1)酶联免疫吸附法，采用抗原与抗体的特异反应将待测物与酶连接，然后通过酶与底物产生颜色反应，用于定量测定。(2)胶体金免疫层析法，该方法操作简单，通常用于定性或者半定量的测定。(3)免疫比浊法，利用抗原抗体反应形成一定结构的免疫复合物，根据复合物在溶液中具有的特殊光学性质进行检测。(4)荧光免疫层析法，利用荧光物质在特定的激发光照射下发射荧光的特点，针对急性炎症时SAA含量进行检测，目前已在医学上进行推广，并且发展迅猛。无论采用何种检测方法，SAA的稳定性在诊断过程中起着非常重要的作用，稳定的SAA蛋白可提高检测过程中的准确度。
然而，野生型SAA在体外的稳定性较差，导致疾病诊断技术应用中的SAA使用期限短、诊断效率低，因此如何提高SAA的稳定性显得尤为重要。
发明内容
鉴于现有技术的不足，本发明的目的在于提供一种与SAA稳定性显著关联的突变位点，以及一种具有更高稳定性的SAA突变体及其编码基因，更加适应在医疗诊断以及科研中的应用。
为了实现本发明的技术目的，发明人通过大量试验摸索和研究，最终以野生型SAA的基因为模板，采用定点突变技术获得编码突变体的基因，随后将编码突变体的基因位点进行重组表达，获得了一种稳定性显著提高的SAA突变体。具体地，本发明的技术方案概况如下：
一种与血清淀粉样蛋白A的稳定性显著关联的突变位点，该突变位点位于野生型血清淀粉样蛋白A的10、26、50和66氨基酸处，所述位点是将第10位的半胱氨酸突变为赖氨酸,第26位的甘氨酸突变为脯氨酸，第50位的丝氨酸突变为缬氨酸，以及第66位的甘氨酸突变为脯氨酸，突变后血清淀粉样蛋白A的稳定性显著提高。
由于按上述突变位点突变后得到的突变体SAA1的稳定性显著提高，因此本发明还保护上述的突变位点在提高野生型血清淀粉样蛋白A的稳定性中的应用。
一种稳定性提高的血清淀粉样蛋白A突变体，所述突变体具有：
(1)SEQ ID NO.1所示的氨基酸序列；或
(2)在SEQ ID NO.1所示的氨基酸序列基础上缺失、替换、***或/和添加一个至几个氨基酸的保守性突变而获得的具有同样稳定性的氨基酸序列。
需要说明的是，本发明所提供的血清淀粉样蛋白A突变体属于载脂蛋白家族中的一员。SEQ ID NO.1所示的氨基酸序列由104个氨基酸残基组成，主要是将血清淀粉样蛋白A的第10位的半胱氨酸突变为赖氨酸，第26位的甘氨酸突变为脯氨酸，第50位的丝氨酸突变为缬氨酸，第66位的甘氨酸突变为脯氨酸。所得突变体命名为SAA1。
一种血清淀粉样蛋白A突变体的编码基因，该基因编码具有SEQ ID NO.1所示的氨基酸序列的蛋白质。
进一步优选地，如上所述的血清淀粉样蛋白A突变体的编码基因，其为SEQ IDNO.2所示的核苷酸序列的DNA分子。需要说明的是，由于同一氨基酸可能有多种不同的密码子来决定，所以编码上述突变型酶的核苷酸序列并不局限于所示序列，也可以是由与所示核苷酸序列突变一个或几个核苷酸形成同义突变得到可编码相同氨基酸序列的核苷酸序列。
本发明还提供一种重组载体，该重组载体携带上述的突变体SAA1的编码基因。所述重组载体为将上述编码基因***出发载体pET-30a的多克隆位点得到的重组表达载体。可用现有的表达载体构建含有所述基因的重组表达载体。使用所述基因构建重组表达载体时，在其转录起始核苷酸前可加上任何一种增强型启动子或组成型启动子，它们可单独使用或与其它的启动子结合使用。此外，使用本发明的基因构建重组表达载体时，还可使用增强子，包括翻译增强子或转录增强子，这些增强子区域可以是ATG起始密码子或邻接区域起始密码子等，但必需与编码序列的阅读框相同，以保证整个序列的正确翻译。所述翻译控制信号和起始密码子的来源是广泛的，可以是天然的，也可以是合成的。翻译起始区域可以来自转录起始区域或结构基因。
本发明还提供一种重组细胞或重组菌，该重组细胞或重组菌包含上述的重组载体。例如，将上述任一所述编码基因***出发载体pET-30a的多克隆位点得到的重组表达载体转化至大肠杆菌BL21-801，得到重组细胞或重组菌。
本发明还提供一种制备突变体SAA1的方法，该方法包括：构建含编码突变型SAA1的核苷酸序列的载体，利用含有突变位点信息的引物，对含有SAA基因的质粒进行扩增得到目的条带后利用同源重组得到重组质粒或直接转化得到突变质粒，测序验证习各步骤得到的载体转化宿主细胞得到重组细胞将载体转化到宿主细胞中，利用抗生素筛选得到正确转化的重组细胞；培养上述的重组细胞并由培养产物中收集突变体SAA1。
本发明还提供一种用于上述血清淀粉样蛋白A突变体的保存液，该保存液的组成为：pH＝7.4-9.0硼酸-硼砂缓冲液+0.9％NaCl+0.8-1.2mM EDTA+0.08-0.12％ProClin300。
本发明还提供上述稳定性提高的血清淀粉样蛋白A突变体在制备体外诊断试剂中的应用。进一步优选地，所述的体外诊断试剂用于诊断细菌、真菌或病毒感染、动脉粥样硬化、心血管疾病、急性移植排斥反应、肿瘤。细菌或病毒感染包括甲型和乙型肝炎、巨细胞病毒感染、varicellae——带状疱疹、传染性单核细胞增多症，甲型流感，细菌性肺炎，streptococ-卡尔咽炎细菌败血症和严重的细菌性败血症。
本发明测试结果显示与未突变的SAA相比，使用本发明改造的SAA1稳定性明显比其它公司购买的SAA高。
本发明的优点和有益效果：本发明对野生型SAA进行定向突变优化，使之适应在临床检测技术中的应用要求，得到突变型SAA1。该突变型SAA1不易降解，增加了SAA1在炎症等疾病的体外检测中的稳定性，降低了试剂的批间差，可应用SAA Serum amyloid AReagentkits(Nephelometry)(此试剂盒由南京立顶生物科技有限公司提供)。
附图说明
图1为目的蛋白SAA的SDS-PAGE检测纯化效果图。
图2为DNA切割酶经过酶切的突变型SAA1与表达载体Pet-30a。
具体实施方式
下面结合实施例和附图来进一步描述本发明，本发明的优点和特点将会随着描述而更为清楚。但是应理解所述实施例仅是范例性的，不对本发明的保护范围构成任何限制。本领域技术人员应该理解的是，在不偏离本发明的精神下可以对技术方案的细节和形式进行修改或替换，但这些修改或替换均落入本发明的保护范围。
实施例1
构建含编码突变型SAA1的核苷酸序列的载体，利用基因合成的方法，合成引物序列如下：
购买于山东山东维真生物科技有限公司的SAA序列为模板，利用对人SAA1基因进行扩增。扩增分为4个反应，分别以为引物(由擎科生物合成)，在50uL反应体系中，10umoL的引物各加入2uL，扩增试剂用Master Mix(擎科)。扩增条件94℃-4min，94℃-30s，60℃-30s，72℃-30s，72℃-10min为一共40个循环。
扩增结束后，以1.5％琼脂糖凝胶电泳，得到目的条带后切胶回收。将回收产物与Pet-30a先利用DAN切割酶进行剪切半小时，再以1.5％琼脂糖凝胶电泳，电泳结果为图2，然后进行胶回收，再利用DAN连接酶进行重组反应，37℃恒温孵育半小时。
取10uL冷却反应液，加入到时100uLDH5@感受态细胞中，轻弹管壁数下混匀，在冰上放置0.5h后42℃热激90秒，冰水浴孵育2min。加入500ul的LB培养基，37℃孵育10min充分复苏。37℃摇菌1h。取100ul菌液均匀涂布在含有氨苄青霉素的平板上。将平板倒置，于37℃过夜培养。第二天挑取单克隆测序。测序结果表明本发明合成的突变型酶的核苷酸序列如序列表中序列2所示。
取测序验证无误的载体以同样转化方法转化到BL21-801感受态细胞中，涂布在含卡那青霉素的平板上，37℃过夜培养。第二天挑取单克隆。
培养并收集重组细胞，提取SAA1：挑取BL21-801-Pet30a-SAA1单菌落各一个，接种到5mLLB液体培养基中，37℃，200rpm震荡培养5h。将5mLLB培养的菌液接种到330mLLB培养基，共接2L，37℃，200rpm震荡培养至OD600至0.6-0.8时，加入50mg/ml的IPTG 79.2μL，28℃，100rpm摇床继续培养18h，。将菌体离心收集，10000rpm离心5min，去掉上清，加48mL非变性裂解液，加PSMF(1:50)960μL，加溶菌酶(1:100)480μL至1mg/ml，涡旋混匀后，4度摇床上放置30min，随后超声20min，4度10500rpm离心40min，取上清进行蛋白分离纯化。
树脂纯化SAA1蛋白：将Ni IDA Beads装入合适的层析柱，用5倍体积的Lysisbuffer平衡树脂。将上述上清蛋白重悬树脂，放置摇床孵育1h，使得树脂充分与目的蛋白SAA1结合，再装入合适的层析柱过柱。用10倍体积的Wash buffer对树脂清洗，将非特异性杂蛋白清洗干净。用5倍体积的Elution buffer，收集洗脱液，既SAA1蛋白。用5倍体积的Elution buffer对树脂清洗，保证树脂的重复利用率。使用3倍体积Lysis buffer与5倍体积的ddH2O平衡填料，最后用5倍体积的20％乙醇平衡，然后等体积20％乙醇中4℃保存。将目的蛋白SAA1使用SDS-PAGE检测纯化效果如图1所示。对纯化蛋白进行浓度测定(BCA法测定)，SAA1浓度大于500mg/L。
SAA1保存液：pH＝9(硼酸-硼砂缓冲液)+0.9％NaCl+1mM EDTA+0.1％Pc300；
对纯化蛋白进行透析处理：透析袋(透过分子量3.5kD)，透析液为200mM的硼酸-硼砂缓冲液，透析液与洗脱的SAA1蛋白液比例为1：10，4℃透析6h换一次透析液，共透析12h。
SAA1稳定性测试(胶乳增强免疫比浊)：
用免疫比浊的方法测定对比SAA的稳定性，测得SAA1的稳定性明显比其它公司的稳定性要高。
测试方法：增强免疫比浊法。
测试仪器：半自动特定蛋白分析仪
测定原理：抗原与抗体特异性结合
测定步骤：
1.测试前试剂盒中的R1(缓冲稀释液)与R2(胶乳抗血清)平衡至室温后再进行测试。
2.将突变SAA1和未突变SAA以及购买的申基生物公司的SAA和北京春雷杰创SAA按适当比例(40倍，80倍稀释)。
3.取出测量杯，先加入缓冲液R1 400ul，然后将2u1抗原稀释液加入测量杯中，放入仪器上的测量通道后10s加入抗血清R2，同时按指示键。
4.仪器将自动开始检测，测试完毕后，自动显示吸光度结果。
5.对每个的第一次测试的吸光度记为0d的试验结果，之后放值37℃培养箱进行加速，之后按操作依次测试第1d，3d，5d，7d，11d，15d的吸光度进行分析。
数据分析：由表1的测试结果可以看出，突变SAA1的吸光度从0-15d是几乎不变，40倍稀释与80倍稀释的CV≤1％，未突变SAA的CV≤15％，而购买的SAA在加速条件下极度不稳定，CV≥20％，并且稀释倍数越高越不稳定。
表1：SAA稳定性测试结果
序列表
<110> 南京立顶生物科技有限公司
<120> 一种稳定的SAA突变体及其在疾病检测中的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 104
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Arg Ser Phe Phe Ser Phe Leu Gly Glu Lys Phe Asp Gly Ala Arg Asp
1 5 10 15
Met Trp Arg Ala Tyr Ser Asp Met Arg Pro Ala Asn Tyr Ile Gly Ser
20 25 30
Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys Arg Gly
35 40 45
Pro Val Gly Val Trp Ala Ala Glu Ala Ile Ser Asp Ala Arg Glu Asn
50 55 60
Ile Pro Arg Phe Phe Gly His Gly Ala Glu Asp Ser Leu Ala Asp Gln
65 70 75 80
Ala Ala Asn Glu Trp Gly Arg Ser Gly Lys Asp Pro Asn His Phe Arg
85 90 95
Pro Ala Gly Leu Pro Glu Lys Tyr
100
<210> 2
<211> 312
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
cgaagcttct tttcgttcct tggcgaggct tttgatgggg ctcgggacat gtggagagcc 60
tactctgaca tgagagaagc caattacatc ggctcagaca aatacttcca tgctcggggg 120
aactatgatg ctgccaaaag gggacctggg ggtgtctggg ctgcagaagc gatcagcgat 180
gccagagaga atatccagag attctttggc catggtgcgg aggactcgct ggctgatcag 240
gctgccaatg aatggggcag gagtggcaaa gaccccaatc acttccgacc tgctggcctg 300
cctgagaaat ac 312
Claims (10)
1.一种与血清淀粉样蛋白A的稳定性显著关联的突变位点，其特征在于，该突变位点位于野生型血清淀粉样蛋白A的10、26、50和66氨基酸处，所述位点是将第10位的半胱氨酸突变为赖氨酸,第26位的甘氨酸突变为脯氨酸，第50位的丝氨酸突变为缬氨酸，以及第66位的甘氨酸突变为脯氨酸，突变后血清淀粉样蛋白A的稳定性显著提高。
2.权利要求1所述的突变位点在提高野生型血清淀粉样蛋白A的稳定性中的应用。
3.一种稳定性提高的血清淀粉样蛋白A突变体，其特征在于，所述突变体具有：
(1)SEQ ID NO.1所示的氨基酸序列；或
(2)在SEQ ID NO.1所示的氨基酸序列基础上缺失、替换、***或/和添加一个至几个氨基酸的保守性突变而获得的具有同样稳定性的氨基酸序列。
4.一种血清淀粉样蛋白A突变体的编码基因，其特征在于，该基因编码具有SEQ IDNO.1所示的氨基酸序列的蛋白质。
5.根据权利要求4所述的血清淀粉样蛋白A突变体的编码基因，其特征在于，所述编码基因为SEQ ID NO.2所示的核苷酸序列的DNA分子。
6.一种携带权利要求4或5所述编码基因的载体、重组细胞或重组菌。
7.根据权利要求6所述的载体、重组细胞或重组菌，其特征在于，所述重组细胞所使用的宿主细胞为BL21-801。
8.一种用于权利要求3所述稳定性提高的血清淀粉样蛋白A突变体的保存液，其特征在于，该保存液的组成为：pH＝7.4-9.0硼酸-硼砂缓冲液+0.9％NaCl+0.8-1.2mM EDTA+0.08-0.12％ProClin300。
9.权利要求3所述稳定性提高的血清淀粉样蛋白A突变体在制备体外诊断试剂中的应用。
10.根据权利要求9所述的应用，其特征在于，所述的体外诊断试剂用于诊断细菌、真菌或病毒感染、动脉粥样硬化、心血管疾病、急性移植排斥反应、肿瘤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910297187.9A CN109957003B (zh) | 2019-04-15 | 2019-04-15 | 一种稳定的saa突变体及其在疾病检测中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910297187.9A CN109957003B (zh) | 2019-04-15 | 2019-04-15 | 一种稳定的saa突变体及其在疾病检测中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109957003A true CN109957003A (zh) | 2019-07-02 |
| CN109957003B CN109957003B (zh) | 2022-04-19 |
Family
ID=67026119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910297187.9A Active CN109957003B (zh) | 2019-04-15 | 2019-04-15 | 一种稳定的saa突变体及其在疾病检测中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109957003B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110746499A (zh) * | 2019-11-28 | 2020-02-04 | 宁波赛珀生物技术有限公司 | 一种血清淀粉样蛋白a突变体及其应用和制备方法 |
| CN117603335A (zh) * | 2024-01-19 | 2024-02-27 | 北京春雷杰创生物科技有限公司 | 人血清淀粉样蛋白a突变体 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996038166A1 (en) * | 1995-06-01 | 1996-12-05 | Queen's University At Kingston | Serum amyloid a protein |
| WO2001021188A1 (en) * | 1999-09-22 | 2001-03-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilization of fprl1 as a functional receptor by serum amyloid a (saa) |
| US20030120037A1 (en) * | 1999-09-22 | 2003-06-26 | Ji Ming Wang | Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA) |
| CN102016059A (zh) * | 2007-12-28 | 2011-04-13 | 依兰制药公司 | 淀粉样变性的治疗和预防 |
| CN106526198A (zh) * | 2016-10-03 | 2017-03-22 | 王贤俊 | 一种组合定向剂优化胶乳偶联抗体检测前白蛋白（pa）的方法 |
| CN108299551A (zh) * | 2018-02-09 | 2018-07-20 | 北京市华信行生物科技有限公司 | 血清淀粉样蛋白a1突变体及其制备方法和应用 |
| CN109072274A (zh) * | 2016-04-14 | 2018-12-21 | 道健康生活医药株式会社 | 淀粉样蛋白球体（aspd）样结构体及医药组合物 |
-
2019
- 2019-04-15 CN CN201910297187.9A patent/CN109957003B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996038166A1 (en) * | 1995-06-01 | 1996-12-05 | Queen's University At Kingston | Serum amyloid a protein |
| WO2001021188A1 (en) * | 1999-09-22 | 2001-03-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilization of fprl1 as a functional receptor by serum amyloid a (saa) |
| US20030120037A1 (en) * | 1999-09-22 | 2003-06-26 | Ji Ming Wang | Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA) |
| CN102016059A (zh) * | 2007-12-28 | 2011-04-13 | 依兰制药公司 | 淀粉样变性的治疗和预防 |
| CN109072274A (zh) * | 2016-04-14 | 2018-12-21 | 道健康生活医药株式会社 | 淀粉样蛋白球体（aspd）样结构体及医药组合物 |
| CN106526198A (zh) * | 2016-10-03 | 2017-03-22 | 王贤俊 | 一种组合定向剂优化胶乳偶联抗体检测前白蛋白（pa）的方法 |
| CN108299551A (zh) * | 2018-02-09 | 2018-07-20 | 北京市华信行生物科技有限公司 | 血清淀粉样蛋白a1突变体及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| C M BEACH ET AL: "Human serum amyloid A protein. Complete amino acid sequence of a new variant", 《BIOCHEM J》 * |
| 郝雪微等: "人血清淀粉样蛋白SAA1蛋白的原核重组表达", 《现代生物医学进展》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110746499A (zh) * | 2019-11-28 | 2020-02-04 | 宁波赛珀生物技术有限公司 | 一种血清淀粉样蛋白a突变体及其应用和制备方法 |
| CN117603335A (zh) * | 2024-01-19 | 2024-02-27 | 北京春雷杰创生物科技有限公司 | 人血清淀粉样蛋白a突变体 |
| CN117603335B (zh) * | 2024-01-19 | 2024-04-30 | 北京春雷杰创生物科技有限公司 | 人血清淀粉样蛋白a突变体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109957003B (zh) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101735319B (zh) | 一种抗gp73蛋白的单克隆抗体、其制备方法和应用 | |
| CN112946260B (zh) | 检测新冠肺炎病毒抗体的荧光免疫层析试剂及其制备方法 | |
| CN101949937A (zh) | 卵巢癌肿瘤标志物he4时间分辨荧光免疫检测试剂盒 | |
| CN102964435B (zh) | 截短型溶血链球菌溶菌素o及利用其的检测试剂盒 | |
| CN109957003A (zh) | 一种稳定的saa突变体及其在疾病检测中的应用 | |
| CN108299551A (zh) | 血清淀粉样蛋白a1突变体及其制备方法和应用 | |
| CN111253478B (zh) | 肺炎支原体抗原及其制备方法和应用 | |
| JPH01163665A (ja) | イムノアツセイおよびそれに使用される生物学的構築体 | |
| CN114276445A (zh) | 轮状病毒重组蛋白特异性抗体、质粒载体及方法 | |
| CN106554411B (zh) | 可用作标准物质的胱抑素c产品、其制备方法及其用途 | |
| CN111548423B (zh) | 肺炎支原体融合抗原及其制备方法和应用 | |
| CN104610443B (zh) | 一种高稳定性重组降钙素原、制备方法及用途 | |
| CN109721651A (zh) | 一种视黄醇结合蛋白检测试剂盒及其临床应用 | |
| CN110964089B (zh) | 一种肺炎支原体抗原 | |
| CN102539778A (zh) | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 | |
| CN104297494B (zh) | 一种抗乙型肝炎病毒x蛋白抗体酶联免疫测定试剂盒及其制备方法 | |
| EP1308730B1 (en) | Method of detecting or assaying hbv | |
| CN111273028B (zh) | rhTSG-6直接竞争ELISA法定量检测试剂盒及其使用方法和应用 | |
| CN112646007B (zh) | 用于结核分枝杆菌检测的组合蛋白及检测试剂 | |
| CN112521461B (zh) | 甲型肝炎病毒重组蛋白的制备及其快速检测方法 | |
| CN110981947B (zh) | ***tp47重组抗原的制备及应用 | |
| CN111273029B (zh) | rhTSG-6双抗体夹心ELISA法定量检测试剂盒及其使用方法和应用 | |
| CN113563484B (zh) | 一种G11-scFv-Nluc双功能活性的融合蛋白及其应用 | |
| CN115094047B (zh) | 一种直扩型Bst DNA聚合酶及其制备方法与应用 | |
| CN110903356B (zh) | 一种猪圆环病毒ii型抗原以及检测猪圆环病毒ii型抗体的胶体金免疫层析试纸条 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220325 Address after: Room 408 / 409 / 410, floor 3, building C6, Jiangsu Life Science Park, No. 9 Weidi Road, Xianlin street, Qixia District, Nanjing, Jiangsu 210000 Applicant after: Nanjing Liding Medical Technology Co.,Ltd. Address before: 210043 8-839, zone a, service trade zone, No. 268, Lidao Road, Baguazhou street, Qixia District, Nanjing, Jiangsu Province Applicant before: Nanjing Liding Biotechnology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |